



ASX AND MEDIA RELEASE

Completion of international financing

1 November 2006: Peplin Limited (ASX:PEP) announced today the completion of the second tranche of the MPM Capital led international financing announced in May 2006.

With the exception of the investment by Peplin non-executive director, Gary Pace which completed in June 2006, the A\$26.5 million international offering was structured in two equal tranches. The second tranche was subject to Peplin satisfying certain performance pre-conditions or milestones. The investors in the international financing comprise MPM Capital, Deerfield, AMP, Orbis and First Choice and all investors completed the second tranche.

Managing Director & CEO Michael Aldridge said this investment successfully completed a very important step in Peplin's strategic growth and development.

"Having successfully passed these important performance milestones we now enjoy a very strong capital position with over \$40 million in cash at hand and have the key resources in place to pursue the development of PEP005 Topical our lead product being developed for the treatment of actinic (solar) keratosis a common pre-cancerous lesion and basal cell carcinoma (BCC) the most common form of skin cancer," he said.

The second tranche of the international offer comprised approximately 18.7 million ordinary shares at A\$0.71 cents per share together with 5.6 million 4 year options exercisable at A\$0.84 per share. Following the closing of the second tranche Peplin would have on issue approximately 184.5 million ordinary shares and 17.1 million options listed on the ASX (ASX:PEPO).

ENDS

Further information:

Michael Aldridge
Managing Director & CEO
Tel: 07-3250 1200
michael.aldridge@peplin.com

Media:

Tim Mullen
Hill & Knowlton
Tel: 02-9286 1215, 02-9286 1272
tmullen@hillandknowlton.com.au

About Peplin

Peplin is focused on the development and commercialisation of prescription human therapeutic products for the treatment of cancer. Its lead compound is PEP005, the first in a new class of investigational agents. Peplin's lead product is PEP005 Topical, which is being studied in clinical trials for the treatment of actinic keratosis (AK) (a pre-cancerous lesion) and non-melanoma skin cancer (NMSC). PEP005 Topical works by a powerful mode of action, directly killing most cancer cells and then recruiting and activating the local immune system to clean-up these dead cancer cells and kill any remaining cancer cells. PEP005 Topical is potentially a rapidly acting and cosmetically attractive non-surgical topical treatment for AK and NMSC. Peplin's product development activities are supported by the Australian Federal Government under its Pharmaceuticals Partnerships Program.

Peplin's earlier stage pipeline is targeted at leukemia (a blood borne cancer) using its lead compound PEP005 in an intravenous formulation (PEP005 IV) and bladder cancer using an intracavitary or intravesical formulation (PEP005 IC). PEP005 has demonstrated selective and potent anti-leukemia activity in pre-clinical disease models. PEP005 induces apoptosis in leukemia cells via the activation of PKC delta. Peplin holds global proprietary rights for PEP005 Topical and other therapeutic applications of PEP005. Its research portfolio of EPUFA compounds opens additional potential opportunities in cancer and pain.